Key result
Transdermal glyceryl trinitrate patches showed changes in bioavailability over 24 hours, with clinical tolerance developing despite maintained arterial vasodilating effects.
Why the study?
How do changes in transdermal glyceryl trinitrate (GTN) bioavailability relate to clinical efficacy and the development of nitrate tolerance over 24 hours?
How do changes in transdermal glyceryl trinitrate (GTN) bioavailability relate to clinical efficacy and the development of nitrate tolerance over 24 hours?
Clinical nitrate tolerance to transdermal GTN patches develops within 24 hours despite maintained arterial vasodilation, likely driven by venous counterregulatory mechanisms.
Answers are grounded in this paper and cite their sources.
Tolerance to transdermal GTN develops within 24 hours despite maintained arterial effects; leaves open venous counterregulation as a key mechanism for further study.
F’atches with glycetyl trinitrate (GTN) provide rather stable plasma concentrations for 24 hours, but clinical efficacy is not maintained. We examined further the pharmacokinetics of transdermal treatment, and the rlelationship between changes in GTN bioavailability and clinical efficacy. The mechanisms of nitrate tolerance were studied by finger plethysmography (FPG), with pulse curve analysis. The GTN plasma concentrations increased after local heating of the patch area, and decreased after cooling. An increase in GTN occurred during exercise in angina patients, but less so after 24 hours. After 24 hours, clinical tolerance was observed despite maintenance of the arterial vasodilating effects (FPG). FPG was well-suited in the rabbit, and proved sensitive also for vasodilation induced by acetylcholine (i.e. by nitric oxide). During patch treatment, changes in GTN bioavailability occur during exercise and over 24 hours, possibly affecting clinical efficacy. Counterregulatory mechanisms for the venous effects appear most important in the development of clinical nitrate tolerance.
No takes yet. Share an insight, caveat, or question.
Tor Ole Klemsdal (1997) studied Angina. Glyceryl trinitrate (GTN) patches was evaluated on GTN bioavailability and clinical efficacy. Transdermal glyceryl trinitrate patches showed changes in bioavailability over 24 hours, with clinical tolerance developing despite maintained arterial vasodilating effects.
Synapse has enriched 10 related papers. Consider them for comparative context: